Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors - 11/11/23
Abstract |
Background |
Tumors of the gastrointestinal tract impose a substantial healthcare burden due to their prevalence and challenging prognosis.
Methods |
We conducted a review of peer-reviewed scientific literature using reputable databases (PubMed, Scopus, Web of Science) with a focus on oncolytic virus therapy within the context of gastrointestinal tumors. Our search covered the period up to the study's completion in June 2023.
Inclusion and exclusion criteria |
This study includes articles from peer-reviewed scientific journals, written in English, that specifically address oncolytic virus therapy for gastrointestinal tumors, encompassing genetic engineering advances, combined therapeutic strategies, and safety and efficacy concerns. Excluded are articles not meeting these criteria or focusing on non-primary gastrointestinal metastatic tumors. Results: Our review revealed the remarkable specificity of oncolytic viruses in targeting tumor cells and their potential to enhance anti-tumor immune responses. However, challenges related to safety and efficacy persist, underscoring the need for ongoing research and improvement.
Conclusion |
This study highlights the promising role of oncolytic virus therapy in enhancing gastrointestinal tumor treatments. Continued investigation and innovative combination therapies hold the key to reducing the burden of these tumors on patients and healthcare systems.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Addressing GI Tumor Challenge: We explore oncolytic virus therapy to mitigate this healthcare burden. |
• | Literature Review: We conducted a comprehensive review of oncolytic virus therapy in GI tumors up to June 2023. |
• | Oncolytic Viruses: Targeting tumors and boosting immunity, but challenges persist, urging ongoing innovation. |
Keywords : Oncolytic viruses, Gastrointestinal neoplasms, Immunotherapy, Genetic engineering, Combined modality therapy
Plan
Vol 168
Article 115627- décembre 2023 Retour au numéro
Article précédent
- Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective
- Khurshid Ahmad, Sibhghatulla Shaikh, Jeong Ho Lim, Syed Sayeed Ahmad, Hee Jin Chun, Eun Ju Lee, Inho Choi
- S100A8/A9: An emerging player in sepsis and sepsis-induced organ injury
- Qian Wang, Gangyu Long, Hong Luo, Xiqun Zhu, Yang Han, You Shang, Dingyu Zhang, Rui Gong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?